The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
Open accessAbstract
Purpose: Radiopeptide therapy using a somatostatin analogue labelled with a beta emitter such as 90 Y/177 Lu-DOTATOC is a new therapeutic option in neuroendocrine cancer. Alternative treatments for patients with refractory disease are rare. Here we report the first-in-human experience with 213 Bi-DOTATOC targeted alpha therapy (TAT) in patients pretreated with beta emitters. Methods: Seven patients with progressive advanced neuroendocrine liver metastases refractory to treatment with 90 Y/177 Lu-DOTATOC were treated with an intraarterial infusion of 213 Bi-DOTATOC, and one patient with bone marrow carcinosis was treated with a systemic infusion of 213 Bi-DOTATOC. Haematological, kidney and endocrine toxicities were assessed according to CTCAE criteria. Radiological response was assessed with contrast-enhanced MRI and 68 Ga-DOTATOC-PET/CT. More than 2 years of follow-up were available in seven patients. Results: The biodistribution of 213 Bi-DOTATOC was evaluable with 440 keV gamma emission scans, and demonstrated specific tumour binding. Enduring responses were observed in all treated patients. Chronic kidney toxicity was moderate. Acute haematotoxicity was even less pronounced than with the preceding beta therapies. Conclusion: TAT can induce remission of tumours refractory to beta radiation with favourable acute and mid-term toxicity at therapeutic effective doses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
Gastroenteropancreatic neuroendocrine tumours
Modlin, I. M., Oberg, K., Chung, D. C., Jensen, R. T., de Herder, W. W., Thakker, R. V., Caplin, M., Delle Fave, G., Kaltsas, G. A., Krenning, E. P., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70410-2 · Cited by 1,748
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456
Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058651 · Cited by 552
Hofmann, M., Maecke, H., Börner, A., Weckesser, E., Schöffski, P., Oei, M., Schumacher, J., Henze, M., Heppeler, A., Meyer, G., et al. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100639 · Cited by 544
Targeted α particle immunotherapy for myeloid leukemia
Jurcic, J. G., Larson, S. M., Sgouros, G., McDevitt, M. R., Finn, R. D., Divgi, C. R., Ballangrud, Å. M., Hamacher, K. A., Ma, D., Humm, J. L., et al. (2002) · Blood · doi:10.1182/blood.v100.4.1233.h81602001233_1233_1239 · Cited by 472
Bodei, L., Cremonesi, M., Ferrari, M., Pacifici, M., Grana, C. M., Bartolomei, M., Baio, S. M., Sansovini, M., & Paganelli, G. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0778-1 · Cited by 428
Waldherr, C., Pless, M., Maecke, H. R., Haldemann, A., & Mueller-Brand, J. (2001) · Annals of Oncology · doi:10.1023/a:1011160913619 · Cited by 396
MIRD Pamphlet No. 24: Guidelines for Quantitative 131I SPECT in Dosimetry Applications
Dewaraja, Y. K., Ljungberg, M., Green, A. J., Zanzonico, P. B., Frey, E. C., SNMMI MIRD Committee, Bolch, W. E., Brill, A. B., Dunphy, M., Fisher, D. R., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.122390 · Cited by 336
Yttrium-90-labelled somatostatin-analogue for cancer treatment
Otte, A., Mueller-Brand, J., Dellas, S., Nitzsche, E., Herrmann, R., & Maecke, H. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78355-0 · Cited by 335
Rolleman, E., Valkema, R., de Jong, M., Kooij, P., & Krenning, E. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-0982-3 · Cited by 321
Kunikowska, J., Królicki, L., Hubalewska-Dydejczyk, A., Mikołajczak, R., Sowa-Staszczak, A., & Pawlak, D. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1833-x · Cited by 238
Production of Ac-225 from Th-229 for Targeted α Therapy
Apostolidis, C., Molinet, R., Rasmussen, G., & Morgenstern, A. (2005) · Analytical Chemistry · doi:10.1021/ac0580114 · Cited by 215
Self-citationMorschhauser, F., Radford, J., Van Hoof, A., Botto, B., Rohatiner, A. Z. S., Salles, G., Soubeyran, P., Tilly, H., Bischof-Delaloye, A., van Putten, W. L. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.6400 · Cited by 206
Apostolidis, C., Molinet, R., McGinley, J., Abbas, K., Möllenbeck, J., & Morgenstern, A. (2005) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2004.06.013 · Cited by 176
Self-citationProduction of actinium-225 for alpha particle mediated radioimmunotherapy.
Boll, R. A., Malkemus, D., & Mirzadeh, S. (2005) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2004.12.003 · Cited by 171
Self-citationLong-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
Sabet, A., Ezziddin, K., Pape, U.-F., Ahmadzadehfar, H., Mayer, K., Pöppel, T., Guhlke, S., Biersack, H.-J., & Ezziddin, S. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.119347 · Cited by 163
Hentic, O., Hammel, P., Couvelard, A., Rebours, V, Zappa, M., Palazzo, M., Maire, F., Goujon, G., Gillet, A., Lévy, P., et al. (2012) · Endocrine-Related Cancer · doi:10.1530/erc-12-0002 · Cited by 162
Miederer, M., Henriksen, G., Alke, A., Mossbrugger, I., Quintanilla-Martinez, L., Senekowitsch-Schmidtke, R., & Essler, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4647 · Cited by 155
End-stage renal disease after treatment with 90 Y-DOTATOC
Cybulla, M., Weiner, S. M., & Otte, A. (2001) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590100599 · Cited by 154
Wild, D., Frischknecht, M., Zhang, H., Morgenstern, A., Bruchertseifer, F., Boisclair, J., Provencher-Bolliger, A., Reubi, J., & Maëcke, H. R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1186 · Cited by 137
Self-citationMorgenstern, A., Bruchertseifer, F., & Apostolidis, C. (2012) · Current Radiopharmaceuticals · doi:10.2174/1874471011205030221 · Cited by 133
Self-citationSartor, O. A., Reid, R. H., Bushnell, D. L., Quick, D. P., & Ell, P. J. (2006) · Cancer · doi:10.1002/cncr.22431 · Cited by 123
Breaking Chemoresistance and Radioresistance with [213Bi]anti-CD45 Antibodies in Leukemia Cells
Friesen, C., Glatting, G., Koop, B., Schwarz, K., Morgenstern, A., Apostolidis, C., Debatin, K., & Reske, S. N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3569 · Cited by 109
Self-citationNorenberg, J. P., Krenning, B. J., Konings, I. R. H. M., Kusewitt, D. F., Nayak, T. K., Anderson, T. L., de Jong, M., Garmestani, K., Brechbiel, M. W., & Kvols, L. K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1264 · Cited by 105
225Ac and 223Ra production via 800MeV proton irradiation of natural thorium targets
Weidner, J. W., Mashnik, S. G., John, K. D., Ballard, B. D., Birnbaum, E. R., Bitteker, L. J., Couture, A. J., Fassbender, M. E., Goff, G. S., Gritzo, R. E., et al. (2012) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2012.07.003 · Cited by 97
Kratochwil, C., López-Benítez, R., Mier, W., Haufe, S., Isermann, B., Kauczor, H., Choyke, P. L., Haberkorn, U., & Giesel, F. L. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0144 · Cited by 94
Self-citationKratochwil, C., Giesel, F. L., López-Benítez, R., Schimpfky, N., Kunze, K., Eisenhut, M., Kauczor, H., & Haberkorn, U. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0004 · Cited by 84
Self-citationMeasurement of the 225Ac half-life
Pommé, S. G., Marouli, M., Suliman, G., Dikmen, H., Ammel, R. V., Jobbágy, V., Dirican, A., Stroh, H., Paepen, J., Bruchertseifer, F., et al. (2012) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2012.07.014 · Cited by 74
Self-citationEffects of therapy with [177Lu-DOTA0,Tyr3]octreotate on endocrine function
Teunissen, J. J. M., Krenning, E. P., de Jong, F. H., de Rijke, Y. B., Feelders, R. A., van Aken, M. O., de Herder, W. W., & Kwekkeboom, D. J. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1151-8 · Cited by 49
Half-lives of 221Fr, 217At, 213Bi, 213Po and 209Pb from the 225Ac decay series
Suliman, G., Pommé, S. G., Marouli, M., Ammel, R. V., Stroh, H., Jobbágy, V., Paepen, J., Dirican, A., Bruchertseifer, F., Apostolidis, C., et al. (2013) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2013.02.008 · Cited by 45
Self-citationDecay data measurements on 213Bi using recoil atoms
Marouli, M., Suliman, G., Pommé, S. G., Ammel, R. V., Jobbágy, V., Stroh, H., Dikmen, H., Paepen, J., Dirican, A., Bruchertseifer, F., et al. (2013) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2012.12.005 · Cited by 24
Self-citation
Cited by
Kratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F., Kopka, K., Apostolidis, C., Haberkorn, U., & Morgenstern, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178673 · Cited by 1,100
Self-citationKratochwil, C., Giesel, F. L., Stefanova, M., Benešová, M., Bronzel, M., Afshar-Oromieh, A., Mier, W., Eder, M., Kopka, K., & Haberkorn, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171397 · Cited by 636
Self-citationKratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191395 · Cited by 505
Self-citationRadioactive Main Group and Rare Earth Metals for Imaging and Therapy
Kostelnik, T. I., & Orvig, C. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00294 · Cited by 483
An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth
Morgenstern, A., Apostolidis, C., Kratochwil, C., Sathekge, M., Krolicki, L., & Bruchertseifer, F. (2018) · Current Radiopharmaceuticals · doi:10.2174/1874471011666180502104524 · Cited by 370
Self-citation
Metadata
- Authors
- Kratochwil, C., Giesel, F. L., Bruchertseifer, F., Mier, W., Apostolidis, C., Boll, R., Murphy, K., Haberkorn, U., & Morgenstern, A.
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2014-07-29
- Volume
- 41
- Issue
- 11
- Pages
- 2106-2119
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W1998403654
- Cited by
- 407
- References
- 33
- FWCI
- 13.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.